| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1997PNAS...94.3262S |
| P356 | DOI | 10.1073/PNAS.94.7.3262 |
| P932 | PMC publication ID | 20357 |
| P698 | PubMed publication ID | 9096381 |
| P5875 | ResearchGate publication ID | 14121328 |
| P50 | author | Karl Mechtler | Q28320558 |
| P2093 | author name string | M L Birnstiel | |
| W Schmidt | |||
| B Trska | |||
| H Kirlappos | |||
| M Buschle | |||
| W Zauner | |||
| P2860 | cites work | Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters | Q56787234 |
| Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation | Q67987672 | ||
| Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 | Q71628036 | ||
| Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides | Q71802858 | ||
| Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte | Q72585325 | ||
| The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity | Q72671428 | ||
| Results of adjuvant interferon study in WHO melanoma programme | Q72673247 | ||
| Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection | Q24561706 | ||
| Transferrin-polycation conjugates as carriers for DNA uptake into cells | Q33562690 | ||
| Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination | Q34235329 | ||
| Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens | Q34291693 | ||
| Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity | Q34334817 | ||
| Cancer vaccines: the interleukin 2 dosage effect | Q34361454 | ||
| Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. | Q34371245 | ||
| Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model | Q34975904 | ||
| Toward a genetic analysis of tumor rejection antigens. | Q35909647 | ||
| Functional analysis of alternatively spliced tyrosinase gene transcripts. | Q36061817 | ||
| Transloading of tumor antigen-derived peptides into antigen-presenting cells | Q36084026 | ||
| The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas | Q36362111 | ||
| Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes | Q36363449 | ||
| Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes | Q36364355 | ||
| T cell priming versus T cell tolerance induced by synthetic peptides | Q36365135 | ||
| Accelerated tumor development in interferon-treated B6.C-Hyal-1 a mice. | Q36371647 | ||
| Cloning and expression of cDNA encoding mouse tyrosinase | Q36424864 | ||
| Naturally-occurring peptide antigens derived from the MHC class-I-restricted processing pathway | Q36713254 | ||
| Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy | Q36752428 | ||
| Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes | Q37093959 | ||
| Antineoplastic activity of poly(L-lysine) with some ascites tumor cells | Q37336102 | ||
| Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: a novel general strategy for the generation of potent cancer vaccines | Q37362679 | ||
| Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. | Q37445352 | ||
| Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes | Q38310540 | ||
| Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes | Q40433302 | ||
| MHC molecules as peptide receptors | Q40485460 | ||
| Chemistry of peptides associated with MHC class I and class II molecules | Q40540085 | ||
| MHC ligands and peptide motifs: first listing | Q40612811 | ||
| Tumor antigens recognized by T lymphocytes | Q40661131 | ||
| Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'. | Q40798553 | ||
| Peptides naturally presented by MHC class I molecules | Q40898177 | ||
| New tumor antigens recognized by T cells | Q40952497 | ||
| Mechanisms of antigen uptake for presentation | Q41102979 | ||
| MHC class I-restricted CTL responses to exogenous antigens | Q41182483 | ||
| Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes | Q41483867 | ||
| A prominent natural H-2 Kd ligand is derived from protein tyrosine kinase JAK1. | Q42811177 | ||
| High Efficiency DNA-Mediated Transformation of Primate Cells | Q44901923 | ||
| Cytokine Gene Therapy with Interleukin-2-Transduced Fibroblasts: Effects of IL-2 Dose on Anti-Tumor Immunity | Q45866935 | ||
| The changing quality of life. | Q46354307 | ||
| Differential effects of interleukin-12 on the development of naive mouse CD4+ T cells | Q52059043 | ||
| Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules | Q55042699 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3262-3267 | |
| P577 | publication date | 1997-04-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Cell-free tumor antigen peptide-based cancer vaccines | |
| P478 | volume | 94 |
| Q84591619 | Adjuvant Properties of Cytosine-Phosphate-Guanosine Oligodeoxynucleotide in Combination with Various Polycations in an Ovalbumin-Vaccine Model |
| Q33778847 | Cross-presentation of tumour antigens: evaluation of threshold, duration, distribution and regulation. |
| Q34280941 | Defined synthetic vaccines |
| Q47793303 | Delivery of Epitopes by the Salmonella Type III Secretion System for Vaccine Development |
| Q29619437 | Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes |
| Q47737897 | Experimental vaccine strategies for cancer immunotherapy |
| Q40618302 | Granulocyte-Macrophage Colony-Stimulating Factor-Based Melanoma Cell Vaccines Immunize Syngeneic and Allogeneic Recipients via Host Dendritic Cells |
| Q83295610 | IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses |
| Q45418238 | Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. |
| Q81251217 | Molecular cancer vaccines: Tumor therapy using antigen-specific immunizations |
| Q46696206 | Pentapeptide commonality between Corynebacterium diphtheriae toxin and the Homo sapiens proteome |
| Q40611124 | Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines |
| Q77148378 | Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines |
| Q35623323 | Preventative and therapeutic vaccines for cervical cancer |
| Q33961091 | Proposing low-similarity peptide vaccines against Mycobacterium tuberculosis |
| Q39300036 | RAFTsomes Containing Epitope-MHC-II Complexes Mediated CD4+ T Cell Activation and Antigen-Specific Immune Responses |
| Q59051222 | Role of Erythropoietin and Other Growth Factors inEx VivoErythropoiesis |
| Q74819799 | Skin delivery of a hybrid liposome/ISCOM vaccine implicates a role for adjuvants in rapid modulation of inflammatory cells involved in innate immunity before the enhancement of adaptive immune responses |
| Q53454509 | Synthetic nanoparticle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo |
| Q35549421 | Targeting dendritic cells for priming cellular immune responses |
| Q36039154 | The immunologist’s grail: Vaccines that generate cellular immunity |
| Q35005960 | Towards patient-specific tumor antigen selection for vaccination |
| Q36084026 | Transloading of tumor antigen-derived peptides into antigen-presenting cells |
Search more.